EDGC Decides on Third-Party Allotment of 165 Billion Won Under Rehabilitation Plan... Massive Dilution at 100 Won Per Share, New Shares Listed on June 12
EDGC decided on a third-party allotment of 165,000,000 shares at 100 won per share, raising 165 billion won, following court approval of its rehabilitation plan. This will cause severe dilution for existing shareholders.
The allotted parties are Haemili Co., Ltd. (110,000,000 shares) and AIT Story Co., Ltd. (55,000,000 shares), strategic investors for M&A. The issue price of 100 won is a ~75.9% discount to the current market price of 415 won, significantly harming existing shareholder value.
Proceeds will be used for repaying rehabilitation claims and operating expenses per the rehabilitation plan. Prior to the issuance, a stock split and cancellation will reduce the outstanding shares.
New shares are expected to be listed on June 12, 2026. Allottees must hold 100% of shares for 6 months from listing, mitigating short-term selling pressure but not avoiding long-term dilution.
[AI Comprehensive Analysis]This rights issuance is unavoidable for the rehabilitation plan, but it results in massive dilution, reducing existing shareholders' stake to about 26.8%. The success of the M&A and new management's performance will be key for stock recovery; short-term downward pressure is likely.
KOSDAQ Filing Information
Filing: [Correction of Description] Report on Major Events (Decision on Paid-in Capital Increase)
Company: Eone Diagnomics Genome Center (245620)
Submission: Eone Diagnomics Genome Center Co., Ltd.